CanSino to test coronavirus vaccine candidate in Argentina and Chile

FILE PHOTO: A volunteer receives an injection from a medical worker from Chinese pharmaceutical company CanSino Biologics Inc. for a late stage-trial against the coronavirus disease (COVID-19), in Oaxaca, Mexico November 6, 2020.REUTERS/Jorge Luis Plata

BEIJING (Reuters) - CanSino Biologics Inc will start testing its coronavirus vaccine candidate in late-stage human trials in Argentina and Chile, the co-founder of the Chinese pharmaceutical company said on Saturday.

The candidate Ad5-nCoV, which goes by the trade name Convidecia, uses a harmless common cold virus to carry genetic information of coronavirus' protein to elicit immune responses, has already begun Phase III trials in Pakistan, Russia and Mexico.